35.10

2.12% 0.73

After Hours: 35.10

Guardant Health Inc (GH)

Overview News Price History Option Chain Financials Why GH Down? Discussions Forecast

Guardant Health Inc stock is traded at $35.10, with a volume of 994.07K. It is up +2.12% in the last 24 hours and up +71.14% over the past month. Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Previous Close:

$34.37

Open:

$35.05

24h Volume:

994.07K

Relative Volume:

0.48

Market Cap:

$4.32B

Revenue:

$643.81M

Net Income/Loss:

$-490.76M

P/E Ratio:

-8.6453

EPS:

-4.06

Net Cash Flow:

$-299.27M

1W Performance:

+14.41%

1M Performance:

+71.14%

6M Performance:

+37.54%

1Y Performance:

+43.85%

1-Day Range:

$34.53

$35.56

1-Week Range:

$30.30

$36.02

52-Week Range:

$15.81

$37.04

Guardant Health Inc Stock (GH) Company Profile

Name

Guardant Health Inc

Sector

Healthcare (1200)

Industry

Diagnostics & Research (57)

Phone

855-698-8887

Address

3100 HANOVER STREET, PALO ALTO

Employee

1,779

Twitter

@guardanthealth

Next Earnings Date

2024-11-06

Latest SEC Filings

GH's Discussions on Twitter

Compare GH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GH Guardant Health Inc	35.10	4.32B	643.81M	-490.76M	-299.27M	-4.06
TMO Thermo Fisher Scientific Inc	521.66	199.82B	42.37B	6.14B	7.78B	15.26
DHR Danaher Corp	238.83	173.66B	23.74B	3.89B	4.98B	7.93
A Agilent Technologies Inc	138.14	38.64B	6.51B	1.29B	1.37B	3.82
IQV Iqvia Holdings Inc	201.43	36.52B	15.32B	1.41B	1.96B	5.95
IDXX Idexx Laboratories Inc	421.76	34.55B	3.84B	866.24M	792.60M	9.80

Guardant Health Inc Stock (GH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy
Jun-03-24	Resumed	Jefferies	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform
Sep-28-23	Initiated	Bernstein	Outperform
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Jul-05-23	Resumed	JP Morgan	Overweight
May-26-23	Upgrade	Citigroup	Neutral → Buy
May-05-23	Initiated	UBS	Buy
Mar-09-23	Downgrade	Citigroup	Buy → Neutral
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral
Oct-19-22	Initiated	Craig Hallum	Buy
Oct-06-22	Initiated	Stephens	Overweight
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Overweight
Apr-28-22	Resumed	BTIG Research	Buy
Feb-24-22	Reiterated	Canaccord Genuity	Buy
Feb-24-22	Reiterated	Citigroup	Buy
Feb-24-22	Reiterated	Cowen	Outperform
Feb-24-22	Reiterated	Morgan Stanley	Overweight
Feb-24-22	Reiterated	SVB Leerink	Outperform
Feb-24-22	Reiterated	Stifel	Buy
Feb-24-22	Reiterated	Wells Fargo	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Jun-15-21	Initiated	Raymond James	Mkt Perform
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Overweight
Jan-11-21	Initiated	Stifel	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jun-12-20	Initiated	BTIG Research	Buy
Feb-21-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Aug-07-19	Reiterated	Canaccord Genuity	Buy
Apr-16-19	Initiated	Canaccord Genuity	Buy
Apr-10-19	Upgrade	BofA/Merrill	Neutral → Buy
Feb-28-19	Reiterated	BofA/Merrill	Neutral
Oct-29-18	Initiated	BofA/Merrill	Neutral
Oct-29-18	Initiated	JP Morgan	Overweight
Oct-29-18	Initiated	William Blair	Outperform

View All

Guardant Health Inc Stock (GH) Latest News

Nov 27, 2024

KAS Team Wins $292.5 Million In Jury Trial of Guardant Health v. Natera - Morningstar

Nov 27, 2024

Advantage Alpha Capital Partners LP Buys New Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat

Nov 27, 2024

Nov 26, 2024

Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.

Nov 26, 2024

Nov 25, 2024